Form 4: Apyx Medical Corp Executive Granted Stock Options

Moshe Citronowicz, Sr. V.P. of Operations at Apyx Medical Corp, was granted stock options for 36,000 shares on January 15, 2025.

Summary

• Moshe Citronowicz, the Sr. V.P. of Operations at Apyx Medical Corporation, was granted stock options.
• The grant occurred on January 15, 2025.
• The options are for 36,000 shares of Apyx Medical Corp common stock.
• The exercise price of the options is $1.42 per share.
• The options vest ratably over a 36-month period, becoming fully vested on January 15, 2028.
• The options expire on January 15, 2035.

Sentiment

Score: 7

Explanation: The document indicates a standard executive compensation practice, which is generally viewed neutrally to positively as it incentivizes management. The sentiment is moderately positive as it suggests confidence in the company's future performance.

Positives

• The granting of stock options to a key executive like the Sr. V.P. of Operations can be seen as an incentive to align their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common practice in the medical device industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages across various industries, including medical technology.
• Companies like Stryker, Medtronic, and Boston Scientific also utilize stock options as part of their executive compensation strategy.
• The vesting schedule of 36 months is a typical vesting period for stock options.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns management's interests with increasing shareholder value.
• The executive is incentivized to improve company performance to increase the value of their options.

Key Dates